Neuromyelitis Optica Spectrum Disorders Clinical Trials
2 recruiting trials for Neuromyelitis Optica Spectrum Disorders. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Neuromyelitis Optica Spectrum Disorders clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Early Phase 1 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1), Tianjin Huanhu Hospital (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Blood draw for the laboratory assessment (procedure, 1 trial), followed by UCAR T-cell.
Track Neuromyelitis Optica Spectrum Disorders trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte...
The goal of this study is to assess the frequency of genetic polymorphisms of the FCG3A in a cohort of Italian patients affected by neuromyelitis optica spectrum disorder (NMOSD)...
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA）...
This is an open label, single-site, dose-escalation study in up to 12 participants with relapsed or refractory Neurological Autoimmune Diseases. This study aims to evaluate the...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Neuromyelitis Optica Spectrum Disorders, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Neuromyelitis Optica Spectrum Disorders, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Neuromyelitis Optica Spectrum Disorders, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.